Get started
GeneDx Holdings Corp.GeneDx Holdings Corp.GeneDx Holdings Corp.

GeneDx Holdings Corp.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

WGS chart


Full chart

WGS upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪2.07 B‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−3.17 USD
Net income (FY)
‪−175.77 M‬ USD
Revenue (FY)
‪202.57 M‬ USD
Shares float
‪21.98 M‬
Beta (1Y)
1.62

Employees


Employees (FY)
‪1 K‬
Change (1Y)
−100 −9.09%
Revenue / Employee (1Y)
‪202.57 K‬ USD
Net income / Employee (1Y)
‪−175.77 K‬ USD

About GeneDx Holdings Corp.


Sector
Health Services
Industry
Medical/Nursing Services
CEO
Katherine A. Stueland
Website
genedx.com
Headquarters
Stamford
Founded
2015
FIGI
BBG00XDHY5P9
GeneDx Holdings Corp. is a patient centered health intelligence company. It engages in transforming healthcare by applying AI and machine learning to multidimensional, longitudinal clinical and genomic data to build dynamic models of human health and defining optimal, individualized health trajectories. The firm, through its Centrellis health intelligence platform, generates a more complete understanding of disease and wellness and provides science-driven solutions to the most pressing medical needs. The company was founded by Eric Schadt in October 2015 and is headquartered in Stamford, CT.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

WGS news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of WGS is 77.40 USD — it has increased by 2.79% in the past 24 hours. Watch GeneDx Holdings Corp. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange GeneDx Holdings Corp. stocks are traded under the ticker WGS.
WGS stock has risen by 7.43% compared to the previous week, the month change is a 9.08% rise, over the last year GeneDx Holdings Corp. has showed a ‪2.84 K‬% increase.
We've gathered analysts' opinions on GeneDx Holdings Corp. future price: according to them, WGS price has a max estimate of 95.00 USD and a min estimate of 70.00 USD. Watch WGS chart and read a more detailed GeneDx Holdings Corp. stock forecast: see what analysts think of GeneDx Holdings Corp. and suggest that you do with its stocks.
WGS reached its all-time high on Feb 12, 2021 with the price of 897.03 USD, and its all-time low was 1.16 USD and was reached on Nov 16, 2023. View more price dynamics on WGS chart.
See other stocks reaching their highest and lowest prices.
WGS stock is 9.00% volatile and has beta coefficient of 1.62. Track GeneDx Holdings Corp. stock price on the chart and check out the list of the most volatile stocks — is GeneDx Holdings Corp. there?
Today GeneDx Holdings Corp. has the market capitalization of ‪2.13 B‬, it has increased by 7.27% over the last week.
Yes, you can track GeneDx Holdings Corp. financials in yearly and quarterly reports right on TradingView.
GeneDx Holdings Corp. is going to release the next earnings report on Mar 18, 2025. Keep track of upcoming events with our Earnings Calendar.
WGS earnings for the last quarter are 0.04 USD per share, whereas the estimation was −0.21 USD resulting in a 118.66% surprise. The estimated earnings for the next quarter are 0.11 USD per share. See more details about GeneDx Holdings Corp. earnings.
GeneDx Holdings Corp. revenue for the last quarter amounts to ‪76.60 M‬ USD, despite the estimated figure of ‪64.98 M‬ USD. In the next quarter, revenue is expected to reach ‪80.22 M‬ USD.
WGS net income for the last quarter is ‪−8.31 M‬ USD, while the quarter before that showed ‪−29.17 M‬ USD of net income which accounts for 71.51% change. Track more GeneDx Holdings Corp. financial stats to get the full picture.
No, WGS doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 22, 2024, the company has ‪1.00 K‬ employees. See our rating of the largest employees — is GeneDx Holdings Corp. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. GeneDx Holdings Corp. EBITDA is ‪−30.13 M‬ USD, and current EBITDA margin is −63.10%. See more stats in GeneDx Holdings Corp. financial statements.
Like other stocks, WGS shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade GeneDx Holdings Corp. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So GeneDx Holdings Corp. technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating GeneDx Holdings Corp. stock shows the neutral signal. See more of GeneDx Holdings Corp. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.